Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. tumor stem
Show results for
Products
Services

Companies

News
Articles

Refine by
Date

  • Older

Tumor Stem Articles & Analysis

7 news found

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...

ByContext Therapeutics Inc.


AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

IRVINE, Calif. – Oct. 29, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, “Co-grafts of Human Stem Cell-Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerate Royal College of Surgeons Rats,” ...

ByAIVITA Biomedical, Inc.


ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

” About ParvOryx ParvOryx (Parvovirus H1) is a wild type rat oncolytic virus that infects and lyses tumor cells in a wide variety of cancers, including glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as ...

ByORYX GmbH & Co. KG


ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

The combination treatment was well tolerated by all patients and led to objective tumor response and significantly prolonged survival times. On the basis of compelling safety, tolerability and efficacy data stemming from both the rGBM trial and from the follow-up program, ORYX requested meetings with the regulatory authorities both in the EU and US to discuss ...

ByORYX GmbH & Co. KG


ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

Secondary endpoints included anti-tumor effects and cellular immune response, plus overall survival. To identify immunological and molecular signatures of responses, three serial liver biopsies (before, during, and after virotherapy) allowed for in-depth analyses of pathological tumor characteristics, tumor-infiltrating immune cells, ...

ByORYX GmbH & Co. KG


GPT Waste’s Head of Business Development completes the Windemere Triathlon

GPT Waste’s Head of Business Development completes the Windemere Triathlon

On Sunday, 3rd July, Mike Callaghan – Head of Business Development at GPT Waste Management Ltd completed the Windermere Triathlon in a bid to raise funds for The Joshua Wilson Brain Tumour Charity. The Windermere Triathlon is in no way for the faint hearted. It is a challenge only undertaken by those strong enough, and brave enough to believe they can reach the finish line. Starting with ...

ByLightsource BP


Agilent Technologies Thought Leader Award Supports Cancer Stem Cell Research at Mount Sinai

Agilent Technologies Thought Leader Award Supports Cancer Stem Cell Research at Mount Sinai

They are using a combination of genomic and proteomic technologies from Agilent to characterize tumor-initiating cells with stem-cell-like properties derived from solid tumors taken from subjects with various types of cancer. ...

ByAgilent Technologies, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT